Vector Science and Therapeutics Corp. Appoints Angus Jackson as Managing Director of Corporate Development

Jackson to lead organic and inorganic growth initiatives, strategic partnerships and corporate development as the Company advances its life sciences and therapeutics platforms

TORONTO, Oct. 19, 2026 /CNW/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the appointment of Angus Jackson as Managing Director of Corporate Development. In this role, Mr. Jackson will assist in the Company's organic and lead the inorganic growth initiatives, with responsibility for advancing strategic partnerships, evaluating acquisition and investment opportunities, and supporting the Company's long-term commercial and corporate development strategy.

Mr. Jackson brings a multidisciplinary background spanning investment banking, corporate law, business strategy and operating experience in the life sciences sector. Most recently, he served as an investment banker at Outcome Capital, a Boston-based boutique investment bank focused on the healthcare and life sciences industries. At Outcome Capital, he advised companies across pharmaceuticals, pharmaceutical services, medical technology and healthcare services on mergers and acquisitions, capital raising and strategic transactions.

Prior to his investment banking career, Mr. Jackson held corporate development and operating responsibilities at a family-owned contract manufacturing business serving the pharmaceutical and life sciences industries, where he was involved in strategic initiatives and acquisitions. Vector believes his combination of transaction execution experience and direct operating exposure positions him to help the Company pursue growth opportunities across its business and technology platforms.

Mr. Jackson holds a Master of Business Administration from the University of Virginia Darden School of Business, a Juris Doctor from the University of Georgia School of Law, and a Master of Laws (LL.M.) from Duke University School of Law, with a focus on law and entrepreneurship. His academic and professional background combines financial analysis, transaction structuring, corporate strategy, entrepreneurship and legal expertise.

Role and Priorities

In his new role, Mr. Jackson will focus on identifying and executing opportunities to accelerate Vector's growth, including commercial expansion, strategic alliances, business development initiatives and selective mergers and acquisitions. He will also work with Company leadership to evaluate opportunities that complement Vector's existing capabilities and support the development and commercialization of its therapeutic delivery technologies, medical devices and peptide-related offerings.

"Disciplined corporate development is essential to turning Vector's technology platforms into lasting commercial value," said Tommy Thompson, Chairman of Vector Science and Therapeutics and former U.S. Secretary of Health and Human Services. "Angus's background in healthcare investment banking, law and pharmaceutical manufacturing gives the Company the expertise to evaluate and execute strategic opportunities with rigor, and we are pleased to welcome him to the team."

"Angus brings a rare combination of transaction experience and hands-on operating knowledge of pharmaceutical manufacturing, which is exactly what Vector needs as we scale," said Russell Starr, President of Vector Science and Therapeutics. "As we evaluate partnerships and acquisitions that complement our delivery technologies and peptide platform, his ability to identify, structure and execute the right opportunities will be an important asset to the Company and our shareholders."

"I am excited to join Vector at an important stage in the Company's development," said Angus Jackson, Managing Director of Corporate Development. "Vector has an opportunity to build on its existing technology platforms, deepen strategic partnerships, and pursue new avenues for commercial growth. I look forward to working with the team to execute a disciplined growth strategy that combines organic expansion with targeted strategic transactions and partnerships."

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing drug delivery technology and pharma-grade peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. Vector's peptides are pharma-grade, not research-grade: they are manufactured under cGMP, FDA, and ISO-compliant conditions, Rx-labeled, and sold directly to physicians for physician use, rather than distributed through the research-only channels associated with research-grade material. The Company's product and intellectual property portfolio is focused on advanced transdermal delivery, precision catheter systems, localized pain management, pancreatic oncology, and smart wound care. Vector is headquartered in Mequon, Wisconsin. For more information, visit https://vectorscience.co/.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding Mr. Jackson's anticipated role and responsibilities, the Company's growth strategy, and the Company's intention to pursue commercial expansion, strategic partnerships, business development initiatives, investments and acquisitions. Forward-looking information is based on management's current expectations and assumptions and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including the risk that the Company does not identify suitable partnerships, investments or acquisitions, that any such transactions are not completed on acceptable terms or at all, that required financing or regulatory and stock exchange approvals are not obtained, or that the anticipated benefits of any transaction are not realized. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update forward-looking information except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Vector Sciences & Therapeutics

Media Contact: Vector Science and Therapeutics Corp. | [email protected] | www.vectorscience.co